A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-29 and is reviewed periodically as new material appears.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Archived from the original on January 11, 2013. "Paye ta plainte" [Pay for your complaint]. Le Groupe F (in French). Archived from the original on February 13, 2019. "Laboratoire de l'égalité" [Equality Lab] (in French). Archived from the original on January 18, 2019. "Paye ton taf" [Pay for your work] (in French). Archived from the original on April 13, 2019. "Délégation aux droits des femmes" [Delegation for Women's Rights]. Assemblée Nationale (in French). Archived from the original on June 24, 2020.
=== 2013–2014: First regulatory actions === In March 2013, the US Financial Crimes Enforcement Network (FinCEN) established regulatory guidelines for "decentralized virtual currencies" such as bitcoin, classifying American bitcoin miners who sell their generated bitcoins as money services businesses, subject to registration and other legal obligations. In May 2013, US authorities seized the unregistered exchange Mt. Gox. In June 2013, the US Drug Enforcement Administration seized ₿11.02 from an individual attempting to use them to purchase illicit drugs. This marked the first time a government agency had seized bitcoins. The FBI seized about ₿30,000 in October 2013 from Silk Road, following the arrest of its founder Ross Ulbricht. In December 2013, the People's Bank of China prohibited Chinese financial institutions from using bitcoin. After the announcement, the value of bitcoin dropped, and Baidu no longer accepted bitcoins for certain services. Buying real-world goods with any virtual currency had been illegal in China since at least 2009.
Threonine–tRNA ligase 1, cytoplasmic, also called threonyl-tRNA synthetase 1, is an enzyme that in humans is encoded by the TARS1 gene. Like its relatives, TARS2 and TARS3, this enzyme functions as a threonine–tRNA ligase, which means it attaches the animo acid threonine to its corresponding transfer RNA as part of RNA-to-protein translation.
Both 123I and 125I emit copious low energy Auger electrons after their decay, but these do not cause serious damage (double-stranded DNA breaks) in cells, unless the nuclide is incorporated into a medication that accumulates in the nucleus, or into DNA (this is never the case is clinical medicine, but it has been seen in experimental animal models). Iodine-125 is also commonly used by radiation oncologists in low dose rate brachytherapy in the treatment of cancer at sites other than the thyroid, especially in prostate cancer. When 125I is used therapeutically, it is encapsulated in titanium seeds and implanted in the area of the tumor, where it remains. The low energy of the gamma spectrum in this case limits radiation damage to tissues far from the implanted capsule. Iodine-125, due to its suitable longer half-life and less penetrating gamma spectrum, is also often preferred for laboratory tests that rely on iodine as a tracer that is counted by a gamma counter, such as in radioimmunoassaying. 125I is used as the radiolabel in investigating which ligands go to which plant pattern recognition receptors (PRRs).
=== Eating positions === Eating positions vary according to the different regions of the world, as culture influences the way people eat their meals. For example, most of the Middle Eastern countries, eating while sitting on the floor is most common, and it is believed to be healthier than eating while sitting at a table. Eating in a reclining position was favored by the Ancient Greeks at a celebration they called a symposium, and this custom was adopted by the Ancient Romans. Ancient Hebrews also adopted this posture for traditional celebrations of Passover.
Sources: en.wikipedia.org
Platt, Harris & Tishkoff (2026) reconstruct likely patterns of interbreeding between Neanderthals and anatomically modern humans on the basis of the study of their X chromosomes, interpreted as indicating that their interbreeding predominantly involved Neanderthal men mating with anatomically modern women. Evidence from the study of Middle and Upper Paleolithic assemblages, indicating that overall anatomically modern human occupations can be distinguished from Neanderthal ones on the basis of tighter and more cohesive clusters of archaeological remains, is presented by Merino-Pelaz & Cobo-Sánchez (2026). Evidence of utility of the study of nonmetric traits at the enamel-dentine junction for distinguishing teeth of Neanderthals and modern humans is presented by Becam, Chevalier & Colard (2026). Kanis et al. (2026) identify amino acid changes in the growth hormone receptor of Neanderthals, including a change driving faster cell growth, and report evidence of more muscle mass in modern humans who inherited the gene encoding the Neanderthal growth hormone receptor through admixture. Zhang et al. (2026) present a new method for identification of evidence of archaic ancestry in modern human genomes, and report evidence of an introgression from an unknown archaic lineage into the ancestors of modern humans before their migration out of Africa. Evidence of effectiveness of the imputation in detection of Neanderthal and Denisovan ancestry in low-coverage ancient genomes is presented by Capodiferro et al. (2026) . Rao et al.
Tibetan Buddhist scholars rely on the north Indian works of scholars such as Asanga, Vasubandhu and Nagarjuna in their interpretation of the 12 nidanas. For example, according to Wayman, Tsongkhapa, attempted to harmonize the presentations of the 12 links found in Nagarjuna and in Asanga. Tsongkhapa also explains how the twelve nidanas can be applied to one life of a single person, two lives of a single person, and three lives of a single person. Discussing the three lifetimes model, Alex Wayman states that the Theravada interpretation is different from the Vajrayana view, because the Vajrayana view places a bardo or an intermediate state (which is denied in Theravada) between death and rebirth. The Tibetan Buddhism tradition allocates the twelve nidanas differently between various lives. Madhyamaka is interpreted in different ways by different traditions. Some scholars accept a version of the shentong view introduced by Dolpopa (1292–1361), which argues that buddha-nature and buddhahood was not dependently originated and thus not empty of itself (but empty of what is not itself). The Gelug school which follows Tsongkhapa's thought rejects this view, and instead holds that all phenomena are said to lack 'inherent' existence (svabhava) and thus, everything is empty and dependently originated. Other Tibetan madhyamakas like Gorampa argue for a more anti-realist view, negating the very existence of all phenomena and seeing them all as illusions.
2C-B is metabolized by the monoamine oxidase (MAO) enzymes MAO-A and MAO-B. Monoamine oxidase inhibitors (MAOIs) such as phenelzine, tranylcypromine, moclobemide, and selegiline may potentiate the effects of 2C-B. This may result in overdose and serious toxicity. There are anecdotal reports of strong potentiation of 2C-B by MAOIs. 2C-B may also have interactions with other medications and drugs.
== Chemistry == Radium only exhibits the oxidation state of +2 in solution. It forms the colorless Ra2+ cation in aqueous solution, which is highly basic and does not form complexes readily. Most radium compounds are therefore simple ionic compounds, though participation from the 6s and 6p electrons (in addition to the valence 7s electrons) is expected due to relativistic effects and would enhance the covalent character of radium compounds such as RaF2 and RaAt2. For this reason, the standard electrode potential for the half-reaction Ra2+ (aq) + 2e- → Ra (s) is −2.916 V, even slightly lower than the value −2.92 V for barium, whereas the values had previously smoothly increased down the group (Ca: −2.84 V; Sr: −2.89 V; Ba: −2.92 V). The values for barium and radium are almost exactly the same as those of the heavier alkali metals potassium, rubidium, and caesium.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.